Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SB3 vs Herceptin in Healthy Males
NCT02075073Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab-dttb in HER2-positive breast cancer and gastric cancer (GC) (3 arms), sponsored by Samsung Bioepis. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity at 57 days, Maximum Serum Concentration at 57 days and 1 more. Started Feb 2014; status: completed.
02
Drugs
trastuzumab-dttb
03
Conditions
HER2-positive breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02075073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075073.